Pfizer Inc. (PFE) Cash Flow Statement

Pfizer Inc. (PFE) generated $13.4B of operating cash flow over the twelve months to 2026-06-30, spent $2.4B on capital expenditure and had free cash flow of $11.0B, according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

PFEPfizer Inc.Follow PFE — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 171.2B
P/E TTM: 39.5
Dividend yield: 5.7%
52-week: —
Next earnings: 3 Nov, in 10 days

Line	FY2009 Dec 09	FY2010 Dec 10	FY2011 Dec 11	FY2012 Dec 12	FY2013 Dec 13	FY2018 Dec 18	FY2019 Dec 19	FY2020 Dec 20	FY2021 Dec 21	FY2022 Dec 22	FY2023 Dec 23	FY2024 Dec 24	FY2025 Dec 25	TTM Jun 26
Operating cash flow	16.59	11.45	20.24	16.75	17.68	15.83	12.59	14.40	32.58	29.27	8.70	12.74	11.70	13.40
Capital expenditure	1.21	1.51	1.66	1.33	1.21	1.98	2.05	2.23	2.71	3.24	3.91	2.91	2.63	-2.42
Free cash flow	15.38	9.94	18.58	15.42	16.48	13.84	10.54	12.18	29.87	26.03	4.79	9.84	9.08	10.99
Dividends paid	5.55	6.09	6.23	6.53	6.58	7.98	8.04	8.44	8.73	8.98	9.25	9.51	9.77	—
Share repurchases	0.00	1.00	9.00	8.23	16.29	12.20	8.87	0.00	0.00	2.00	0.00	0.00	—	—
Stock-based compensation	0.35	0.41	0.42	0.48	0.52	0.92	0.69	0.76	1.18	0.87	0.53	0.88	0.80	—

USD billions · SEC XBRL

Pfizer Inc. — questions

What is Pfizer Inc.'s operating cash flow?: $13.4B over the twelve months to 2026-06-30.
How much does Pfizer Inc. spend on capital expenditure?: $2.4B over the twelve months to 2026-06-30.
What is Pfizer Inc.'s free cash flow?: $11.0B over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.

Every figure on this page comes from Pfizer Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.